Leo O'Connor

Aiming to increase test performance, the developers are integrating separate sensors to detect protein and nucleic acid biomarkers for SARS-CoV-2 in a single platform.

Better collaboration as well as a coordinated response will be necessary for the next pandemic, Dx manufacturers, laboratorians, and a government official said.

The firm wants to reduce the threat of going to market with a product too quickly without premarket planning, which it said could damage its reputation.

The firm has licensed technology from Imec that captures breath aerosols. Imec also conducted early development of MiDiagnostics' qPCR instrument.

Though the firm's financial results suffered from a lack of access to hospital lab customers in Q3, such access is already better in Q4, it said.

The firm's CEO said it stands to benefit from COVID-19 testing contributions if the pandemic continues and a strong base business as the pandemic weakens.

The acquisition of Cernostics and its TissueCypher Barrett's Esophagus Assay provides a route for Castle to enter gastrointestinal testing.

The firm is developing a SARS-CoV-2 antigen test that could cost $2 or less while working on lateral flow assays for several neglected diseases.

The firm more than doubled its COVID-19 testing-related revenues during Q3 compared to a year ago. Around 84 percent of the revenues were for rapid screening tests.

The firm has started a project under a government contract to enable its expansion into human in vitro diagnostic testing with a seven-part leukocyte differential point-of-care analyzer.